Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Avacta’s Optim® 1000 Helps De-risk Preformulation Studies

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
Optim 1000 provides a high quality, bespoke biophysical characterization service.

Avacta Analytical has recently undertaken preformulation studies for a new targeted secretion inhibitor (TSI) for Syntaxin Ltd, using its expertise in protein analysis and the Optim 1000 instrument to provide a high quality, bespoke biophysical characterization service.

Dr Andy Hooker, Head of CMC and Quality Management at Syntaxin, explained: “Undertaking preformulation studies requires significant resources to enable the necessary data to be obtained as quickly as possible, and presents a number of challenges. The large quantities of high quality material required to carry out these studies may be difficult to obtain and, in the early drug development stages, there is a high demand for a full range of investigations. Quite simply, the more formulations assessed, the more material is needed as the techniques are frequently destructive.”

“The Optim 1000 uses small amounts of material, significantly reducing the volume of material required and enabling large amounts of data to be acquired in a short period of time. This was a major benefit, as it eliminated the need to provide large amounts of material. As the entire study used less than 320 mg, we were able to rapidly screen a variety of different formulations at low cost. This allowed more formulations to be studied - and unsuitable formulations to be discarded - early on in the development process, de-risking the programme. Avacta offered expert scientific guidance throughout the study, and having a partner who really understood the TSI technology was invaluable.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Avacta Sign Third Distribution Agreement with Pall Life Sciences
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market.
Friday, September 28, 2012
Avacta Analytical Partners with UCL
Avacta Analytical is partnering with University College London (UCL) as an industrial sponsor of the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies.
Friday, November 18, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Genome of 6000-Year-Old Barley Sequenced
Researchers have successfully sequenced the genome of Chalcolithic barley grains for the first time.
3D Models May Yield Ovarian Cancer Insights
Researchers are developing new tools to decipher ovarian cancer developments through a 3D printing technology.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!